PMID- 35851010
OWN - NLM
STAT- MEDLINE
DCOM- 20220721
LR  - 20220803
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 12
IP  - 7
DP  - 2022 Jul 18
TI  - SARS-CoV-2 vaccination, ABO blood group and risk of COVID-19: population-based 
      cohort study.
PG  - e059944
LID - 10.1136/bmjopen-2021-059944 [doi]
LID - e059944
AB  - OBJECTIVE: To compare outcomes between O and non-O blood groups, and by modified 
      RNA (mRNA) and adenovirus-vectored (Ad-V) vaccines. DESIGN: Population-based 
      cohort study. SETTING: All of Ontario, Canada. Linked data sets captured clinical 
      encounters, vaccinations and laboratory testing for SARS-CoV-2. PARTICIPANTS: 
      Individuals aged 12+ years with known ABO blood group and free of SARS-CoV-2 
      before 15 January 2021. MAIN OUTCOMES MEASURES: The main exposure, first 
      SARS-CoV-2 vaccination, was modelled in a time-varying manner. O and non-O blood 
      group was known prior to vaccination. SARS-CoV-2 infection, and severe COVID-19 
      (hospitalisation or death), were assessed starting 14 days after vaccination, up 
      to 27 June 2021. RESULTS: 2 472 261 individuals were included. 1 743 916 (70.5%) 
      had at least one vaccination, of which 24.6% were fully vaccinated. Those 
      vaccinated were more likely to be women, older in age, residing in a 
      higher-income area and have higher rates of certain comorbid conditions, like 
      cancer, diabetes and hypertension. Relative to unvaccinated, after receiving 
      their first mRNA (adjusted HR (aHR) 0.46, 95% CI 0.44 to 0.47) or Ad-V (aHR 0.49, 
      95% CI 0.44 to 0.54) vaccine, the risk of SARS-CoV-2 infection was lower, as was 
      severe COVID-19 (aHR 0.29, 95% CI 0.20 to 0.43 (mRNA); aHR 0.29, 95% CI 0.26 to 
      0.33 (Ad-V)). Stratifying by blood group produced similar results. For example, 
      after first mRNA vaccination, the aHR of severe COVID-19 was 0.31 (95% CI 0.27 to 
      0.36) among non-O blood groups, and 0.27 (95% CI 0.22 to 0.32) among O blood 
      groups, relative to unvaccinated. Fully vaccinated individuals had the lowest 
      risk of SARS-CoV-2 and severe COVID-19. CONCLUSIONS: SARS-CoV-2 infection and 
      severe COVID-19 are reduced by vaccination. This effect does not vary by vaccine 
      type or blood group, but is more pronounced among fully, than partially, 
      vaccinated individuals.
CI  - (c) Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No 
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ray, Joel G
AU  - Ray JG
AUID- ORCID: 0000-0003-1635-4658
AD  - Medicine, St. Michael's Hospital, Toronto, Ontario, Canada RayJ@smh.ca.
AD  - ICES, Toronto, Ontario, Canada.
FAU - Park, Alison L
AU  - Park AL
AD  - ICES, Toronto, Ontario, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220718
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (ABO Blood-Group System)
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (RNA, Messenger)
RN  - 0 (Viral Vaccines)
SB  - IM
MH  - ABO Blood-Group System
MH  - *COVID-19/epidemiology/prevention & control
MH  - COVID-19 Vaccines
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Ontario/epidemiology
MH  - RNA, Messenger
MH  - SARS-CoV-2
MH  - Vaccination
MH  - *Viral Vaccines
PMC - PMC9297000
OTO - NOTNLM
OT  - Blood bank & transfusion medicine
OT  - COVID-19
OT  - Epidemiology
OT  - HAEMATOLOGY
OT  - INFECTIOUS DISEASES
COIS- Competing interests: None declared.
EDAT- 2022/07/20 06:00
MHDA- 2022/07/22 06:00
PMCR- 2022/07/18
CRDT- 2022/07/19 07:59
PHST- 2022/07/19 07:59 [entrez]
PHST- 2022/07/20 06:00 [pubmed]
PHST- 2022/07/22 06:00 [medline]
PHST- 2022/07/18 00:00 [pmc-release]
AID - bmjopen-2021-059944 [pii]
AID - 10.1136/bmjopen-2021-059944 [doi]
PST - epublish
SO  - BMJ Open. 2022 Jul 18;12(7):e059944. doi: 10.1136/bmjopen-2021-059944.